Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan B Miller

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
American Heart Journal|July 3, 2002
Diuretic resistance predicts mortality in patients with advanced heart failureGerald W Neuberg, Alan B Miller, Chris M O'Connor, et al.
American Journal of Therapeutics|July 17, 2010
Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fractionNorman C Wang, Jonathan P Piccini, Marvin A Konstam, et al.
Journal of the American College of Cardiology|October 11, 2014
Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF studyG Michael Felker, John R Teerlink, Javed Butler, et al.
European Journal of Heart Failure|December 11, 2012
Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillationDavid P Kao, Gordon Davis, Ryan Aleong, et al.
Circulation|March 17, 2010
Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trialMichael R Zile, William H Gaasch, Inder S Anand, et al.
American Heart Journal|April 21, 2009
Prospective assessment of the occurrence of anemia in patients with heart failure: results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) RegistryKirkwood F Adams, James H Patterson, John H Patterson, et al.
American Heart Journal|May 4, 2010
Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) programChristopher M O'Connor, Alan B Miller, John E A Blair, et al.
European Journal of Heart Failure|May 27, 2015
Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trialMichael R MacDonald, Lilin She, Torsten Doenst, et al.
Circulation|August 31, 2016
Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure)Mark C Petrie, Pardeep S Jhund, Lilin She, et al.
Plos One|October 17, 2012
Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphismsChristopher M O'Connor, Mona Fiuzat, Peter E Carson, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
American Heart Journal|July 3, 2002
Diuretic resistance predicts mortality in patients with advanced heart failureGerald W Neuberg, Alan B Miller, Chris M O'Connor, et al.
American Journal of Therapeutics|July 17, 2010
Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fractionNorman C Wang, Jonathan P Piccini, Marvin A Konstam, et al.
Journal of the American College of Cardiology|October 11, 2014
Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF studyG Michael Felker, John R Teerlink, Javed Butler, et al.
European Journal of Heart Failure|December 11, 2012
Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillationDavid P Kao, Gordon Davis, Ryan Aleong, et al.
Circulation|March 17, 2010
Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trialMichael R Zile, William H Gaasch, Inder S Anand, et al.
American Heart Journal|April 21, 2009
Prospective assessment of the occurrence of anemia in patients with heart failure: results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) RegistryKirkwood F Adams, James H Patterson, John H Patterson, et al.
American Heart Journal|May 4, 2010
Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) programChristopher M O'Connor, Alan B Miller, John E A Blair, et al.
European Journal of Heart Failure|May 27, 2015
Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trialMichael R MacDonald, Lilin She, Torsten Doenst, et al.
Circulation|August 31, 2016
Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure)Mark C Petrie, Pardeep S Jhund, Lilin She, et al.
Plos One|October 17, 2012
Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphismsChristopher M O'Connor, Mona Fiuzat, Peter E Carson, et al.
Pageof 5